Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;69(3):e29540.
doi: 10.1002/pbc.29540. Epub 2021 Dec 31.

Resource-appropriate selection of osteosarcoma treatment protocols in low- and middle-income countries

Sharada Mailankody  1   2 , Venkatesan Sampath Kumar  3 , Shah Alam Khan  3 , Shripad D Banavali  4 , Jyoti Bajpai  4
Affiliations
Review

Resource-appropriate selection of osteosarcoma treatment protocols in low- and middle-income countries

Sharada Mailankody et al. Pediatr Blood Cancer. 2022 Mar.

Abstract

Osteosarcoma is a rare malignancy; however, it is still the most common primary bone tumor in adolescents and young adults. Chemotherapy improves survival indubitably in osteosarcoma; nevertheless, the concern is the stagnant progress since the last several decades. There are a handful of active agents and unresolved issues, especially in choosing the ideal chemotherapy regimen. The oncology community is in equipoise regarding the position of high-dose methotrexate (HDMTX), mandatory or adjunct. The choice of therapy becomes widely relevant, including in low- and middle-income countries (LMIC), where HDMTX administration brings additional complexities. Research into novel non-HDMTX-based protocols adapted to the available resources is pivotal in improving disease outcomes, especially in LMIC. The current review focuses on real-world challenges in decision-making and provides a comprehensive overview of the evolution of treatment protocols in LMIC.

Keywords: current management strategies; low- and middle-income countries; non-high-dose methotrexate protocols; osteosarcoma; practical considerations.

PubMed Disclaimer

References

REFERENCES

    1. Cancer facts and figures. American Cancer Society; 2020. Accessed May 5, 2020. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-...
    1. Lokuhetty D, White ISC, Valerie A, eds. WHO Classification of Tumours. Soft Tissue and Bone Tumours. 5th ed. International Agency for Research on Cancer (IARC); 2020.
    1. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314(25):1600-1606.
    1. Strauss SJ, Whelan JS. Current questions in bone sarcomas. Curr Opin Oncol. 2018;30(4):252-259.
    1. Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17(10):1396-1408.

LinkOut - more resources